New generation vaccines against bluetongue virus

• Autorzy: Niedbalski W. , Fitzner A.
• Języki publikacji: EN

Abstrakty

EN

Over the last three decades, a variety of approaches have been investigated to develop new types of bluetongue virus (BTB) vaccines, ranging from baculovirus-expressed subunit vaccines to live vector vaccines. DNA vaccines against BTV consist of DNA plasmid expressing different BTV proteins after inoculation of the animals. The recombinant viral vector vaccines against BTV are based on recombinant viruses that express desired BTV antigens in the host upon inoculation. Viruses such as vaccinia, modified vaccinia Ancara (MVA), capripox, canarypox, herpes, myxoma and fowlpox viruses have been used as vectors of BTV genes. The reverse genetics (RG) systems for BTV are useful tools for BTV vaccine development. Disabled infectious single-cycle (DISC) vaccines make it possible to restore virus replication and can be used for differentiating infected from vaccinated animals (DIVA). These vaccines are based on the production of a modified virus with a deletion in one or more genes that are essential for virus replication. Another approach for BTV vaccine development using RG is the disabled infectious single-animal (DISA) vaccine, generated by deletion of NS3/NS3a expression. DISC and DISA vaccines can mimic the natural tropism of the virus and can express BTV proteins at the site of infection. Important advantages of these new generation vaccines over the conventional BTV vaccines are their high efficacy as well as the possibility of applying them for DIVA. At present, there are a number of novel laboratoryscale BTV vaccines that could meet vaccine profiles required for different field situations. However, further development and licensing of these vaccine candidates for many BTV serotypes is needed in order to prepare for future BT outbreaks. To date, all novel BTV vaccines described in this paper are still under laboratory testing. They are not available commercially, and the time of their application in the field is still indefinite.

Słowa kluczowe

EN

domestic animal; wild animal; ruminant; bluetongue virus; new generation vaccine; vaccine; experimental vaccine; reverse genetics

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2018
• Tom: 74
• Numer: 06
• Opis fizyczny: p.377-382,ref.

Twórcy

autor

Niedbalski W.

• Department of Foot and Mouth Disease, National Veterinary Research Institute, Wodna 7, 98-220 Zdunska Wola, Poland

autor

Fitzner A.

• Department of Foot and Mouth Disease, National Veterinary Research Institute, Wodna 7, 98-220 Zdunska Wola, Poland

Bibliografia

• Anderson J., Hagglund S., Breard E., Comtet L., Lovgren Bengtsson K., Pringle J., Zientara S., Valarcher J. F.: Evaluation of the immunogenicity and experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle. Clin. Vaccine Immunol. 2013, 20, 1115-1122.
• Batten C. A., Maan S., Shaw A. E., Maan N. S., Mertens P. P.: A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res. 2008, 137, 56-63.
• Boone J. D., Balasuriya U. B., Karaca K., Audonnet J. C., Yao J., He L., Nordgren R., Monaco F., Savini G., Gardner I. A., Maclachlan N. J.: Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP3 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007, 25, 672-678.
• Boyce M., Celma C. C., Roy P.: Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts. J. Virol. 2008, 82, 8339-8348.
• Calistri P., Giovannini A., Conte A., Nannini D., Santucci U., Patta C., Rolesu S., Caporale V.: Bluetongue in Italy: Part I. Vet. Ital. 2004, 40, 243-251.
• Calvo-Pinilla E., Navasa N., Anguita J., Ortego J.: Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 2012, 7. doi: 10.1371/journal.pone.0034735.
• Calvo-Pinilla E., Rodriguez-Calvo T., Sevilla N., Ortego J.: Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR (–/–) mice against lethal bluetongue infection. Vaccine 2009, 28, 437-445.
• Celma C. C., Boyce M., van Rijn P. A., Eschbaumer M., Wernike K., Hoffmann B., Beer M., Haegeman A., De Clercq K., Roy P.: Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. J. Virol. 2013, 87, 9856-9864.
• Celma C. C., Stewart M., Wernike K., Eschbaumer M., Gonzalez-Mollenda L., Breard E., Schulz C., Hoffmann B., Haegeman A., De Clercq K., Zientara S., van Rijn P. A., Beer M., Roy P.: Replication-deficient particles: new insights into the next generation of bluetongue virus vaccines. J. Virol. 2017, 91. doi: 10.1128/JVI.01892-16.
• Feenstra F., Maris-Veldhuis M., Daus F. J., Tacken M. G., Moormann R. J., van Gennip R. G., van Rijn P. A.: VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA. Vaccine 2014, 32, 7108-7114.
• Feenstra F., van Gennip R. G., Maris-Veldhuis M., Verheij E., van Rijn P. A.: Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge. J. Gen. Virol. 2014, 95, 2019-2029.
• Feenstra F., van Gennip R. G., van de Water S. G., van Rijn P. A.: RNA elements in open reading frames of the bluetongue virus genome are essential for virus replication. PLoS One 2014, 9. doi: 10.1371/journal.pone.0092377. eCollection 2014.
• Franceschi V., Capocefalo A., Calvo-Pinilla E., Redaelli M., Mucignat-Caretta C., Mertens P., Ortego J., Donofrio G.: Immunization of knock-out alpha/beta interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 2011, 29, 3074-3082.
• Gethmann J., Huttner K., Heyne H., Probst C., Ziller M., Beer M., Hoffmann B., Mettenleiter T. C., Conraths F. J.: Comparative study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 2009, 27, 4118-4126.
• Huismans H., van der Walt N. T., Cloete M., Erasmus B. J.: Isolation of a capsid protein of a bluetongue virus that induces a protective immune response in sheep. Virology 1987, 157, 172-179.
• Jabbar T. K., Calvo-Pinilla E., Mateos F., Gubbins S., Bin-Tarif A., Bachanek-Bankowska K., Alpar O., Ortego J., Takamatsu H. H., Mertens P. P., Castillo-Olivares J.: Protection of IFNAR (–/–) mice against bluetongue virus serotype 8 by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 2013, 8. doi: 10.137/journal.pone.0060574.
• Legisa D. M., Perez Aguirreburualde M. S., Gonzalez F. N., Marin-Lopez A., Ruitz V., Wigdorovitz A., Martinez-Escribano J. A., Ortego J., Dus Santos M. J.: An experimental subunit vaccine based on bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(–/–) mice. Vaccine 2015, 33, 2614-2619.
• Li J., Yang T., Xu Q., Sun E., Feng Y., Lv S., Zhang Q., Wang H., Wu D.: DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1. Appl. Microbiol. Biotechnol. 2015, 99, 8643-8652.
• Lobato Z. I., Coupar B. E., Gray C. P., Lunt R., Andrew M. E.: Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet. Immunol. Immunopathol. 1997, 59, 293-309.
• Maclachlan N. J., Mayo C. E.: Potential strategies for control of bluetongue, a global emerging, Culicoides-transmitted viral disease of ruminant livestock and wildlife. Antiviral Res. 2013, 99, 79-90.
• Maclachlan N. J., Drew C. P., Darpel K. E., Worwa G.: The pathology and pathogenesis of bluetongue. J. Comp. Pathol. 2009, 141, 1-16.
• Marin-Lopez A., Ortego J.: Generation of recombinant modified vaccinia virus Ankara encoding VP2, NS1, and VP7 proteins of bluetongue virus. Methods Mol. Biol. 2016, 1349, 137-150.
• Marin-Lopez A., Otero-Romero I., de la Poza F., Menaya-Vargas R., Calvo-Pinilla E., Benavente J., Martinez-Costas J. M., Ortego J.: VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(–/–) mice. Antiviral Res. 2014, 110, 42-51.
• Matsuo E., Celma C. C., Boyce M., Viarouge C., Sailleau C., Dubois E., Breard E., Thiery R., Zientara S., Roy P.: Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge. J. Virol. 2011, 85, 10213-10221.
• Mertens P. P., Maan S., Samuel A., Attoui H.: Orbivirus, Reoviridae, [in:] Fauquet C. M., Mayo M. A., Maniloff J., Desselberger U., Ball L. A. (eds): Virus taxonomy: VIIIth report of the ICTV, Elsevier/Academic Press, London 2005, p. 466-483.
• Mertens P. P., Diprose J.: The bluetongue virus core: a nano-scale transcription machine. Virus Res. 2004, 101, 29-43.
• Mohd Jaafar F., Belhouchet M., Vitour D., Adam M., Breard E., Zientara S., Mertens P. P., Attoui H.: Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect alpha/beta interferon-receptor knock-out (IFNAR(–/–)) mice from homologous lethal challenge. Vaccine 2014, 32, 4059-4067.
• Niedbalski W.: Bluetongue vaccines in Europe. Pol. J. Vet. Sci. 2011, 14, 299-304.
• Niedbalski W.: Strategia zwalczania choroby niebieskiego języka w Europie. Med. Weter. 2015, 71, 206-2010.
• Niedbalski W., Kęsy A.: Choroba niebieskiego języka – szczepienia profilaktyczne w Europie. Med. Weter. 2009, 65, 79-83.
• Noad R., Roy P.: Bluetongue vaccines. Vaccine 2009, 27, Suppl. 4, D86-89.
• Rijn P. A. van., Daus F. J., Maris-Veldhuis M. A., Feenstra F., van Gennip R. G.: Bluetongue disabled infectious single animal (DISA) vaccine: studies on the optimal route and dose in sheep. Vaccine 2017, 35, 231-237.
• Rijn P. A., van., Geurts Y., van der Spek A. N., Veldman D., van Gennip R. G.: Bluetongue virus serotype 6 in Europe in 2008 – emergence and disappearance of an unexpected non-virulent BTV. Vet. Microbiol. 2012, 158, 23-32.
• Roy P.: Bluetongue virus proteins and particles and their role in virus entry, assembly, and release. Adv. Virus Res. 2005, 64, 69-123.
• Roy P.: Use of baculovirus expression vector: development of diagnostic reagents, vaccines and morphological counterparts of bluetongue virus. FEMS Microbiol. Immunol. 1990, 2, 223-234.
• Roy P., Bishop D. H., LeBlois H., Erasmus B. J.: Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994, 12, 805-811.
• Roy P., Boyce M., Noad R.: Prospects for improved bluetongue vaccines. Nat. Rev. Microbiol. 2009, 7, 120-128.
• Saegerman C., Berkvens D., Mellor P. S.: Bluetongue epidemiology in the European Union. Emerg. Infect. Dis. 2008, 14, 539-544.
• Said A., Damiani A., Ma G., Kalthoff D., Beer M., Osterrieder N.: An equine herpesvirus 1 (EHV-1) vectored H1 vaccine protects against challenge with swine-origin influenza virus H1N1. Vet. Microbiol. Infect. Dis. 2011, 154, 113-123.
• Sailleau C., Breard E., Viarouge C., Vitour D., Romey A., Garnier A., Fablet A., Lowenski S., Gorna K., Caignard G., Pagneux C., Zientara S.: Re-emergence of bluetongue virus serotype 8 in France, 2015.Transbound. Emerg. Dis. 2017, 64, 998-1000.
• Savini G., Hamers C., Conte A., Miglaccio P., Bonfini B., Teodori L., Di Ventura M., Hudelet P., Schumacher C., Caporale V.: Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle. Vet. Microbiol. 2009, 133, 1-8.
• Savini G., MacLachlan N. J., Sanchez-Vizcaino J. M., Zientara S.: Vaccines against bluetongue in Europe. Comp. Immunol. Microbiol. Infect. Dis. 2008, 31, 101-120.
• Sperlova A., Zendulkova D.: Bluetongue: a review. Vet. Med. 2011, 56, 430-452.
• Stewart M., Dovas C. I., Chatzinasiou E., Athmaram T. N., Papanastassopoulou M., Papadopoulos O., Roy P.: Protective efficacy of bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012, 30, 2131-2139.
• Stewart M., Dubois E., Sailleau C., Breard E., Viarouge C., Desprat A., Thiery R., Zientara S., Roy P.: Bluetongue virus serotype 8 virus-like particles protect sheep against virulent infection as a single or multi-serotype cocktail immunogen. Vaccine 2013, 31, 553-558.
• Thuenemann E. C., Meyers A. E., Verwey J., Rybicki E. P., Lomonossoff G. P.: A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol. J. 2013, 11, 839-846.
• Top S., Foucras G., Deplanche M., Rives G., Calvalido J., Comtet L., Bertagnoli S., Meyer G.: Myxomavirus as a vector for the immunization of sheep: protection study against challenge with bluetongue virus. Vaccine 2012, 30, 1609-1616.
• Verwoerd D. W.: History of Orbivirus research in South Africa. J. S. Afr. Vet. Assoc. 2012, 83:532. doi: 10.4102/jsava.v83i1.532
• Verwoerd D. W., Erasmus B. J.: Bluetongue, [in]: Tustin R. C., Coetzer J. A. (eds): Infectious disease of livestock. Oxford University Press, Cape Town 2004, p. 1201-1220.
• Wackerlin R., Eschbaumer M., Konig P., Hoffmann B., Beer M.: Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle. Vaccine 2010, 28, 4348-4355.
• Wade-Evans A. M., Romero C. H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., Fleming M. J., Mertens P. P., Black D. N.: Expression of the major core structural protein (VP7) of bluetongue virus by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotyping bluetongue virus challenge. Virology 1996, 220, 227-231.
• Walton T. E.: The history of bluetongue and a current global overview. Vet. Ital. 2004, 40, 31-38.
• Zientara S., MacLachlan N. J., Calistri P., Sanchez-Vizcaino J. M., Savini G.: Bluetongue vaccination in Europe. Expert Rev. Vaccines 2010, 9, 989-991.
• Zientara S., Sailleau C., Viarouge C., Höper D., Beer M., Jenckel M., Hoffmann B., Romey A., Bakkali-Kassimi L., Fablet A., Vitour D., Breard E.: Novel bluetongue virus in goats, Corsica, France, 2014. Emerg. Infect. Dis. 2014, 20, 2123-2125.

Identyfikatory

DOI

10.21521/mw.6039